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Abstract
Background: Substance use during sex is associated with sexual risk behavior among men who have sex with men (MSM),
and MSM continue to be the group at highest risk for incident HIV in the United States. The objective of this study is to test
the efficacy of a group-based, cognitive-behavioral intervention to reduce risk behavior of substance-using MSM, compared
to a randomized attention-control group and a nonrandomized standard HIV-testing group.
Methods and Findings: Participants (n=1,686) were enrolled in Chicago, Los Angeles, New York City, and San Francisco and
randomized to a cognitive-behavioral intervention or attention-control comparison. The nonrandomized group received
standard HIV counseling and testing. Intervention group participants received six 2-h group sessions focused on reducing
substance use and sexual risk behavior. Attention-control group participants received six 2-h group sessions of videos and
discussion of MSM community issues unrelated to substance use, sexual risk, and HIV/AIDS. All three groups received HIV
counseling and testing at baseline. The sample reported high-risk behavior during the past 3 mo prior to their baseline visit:
67% reported unprotected anal sex, and 77% reported substance use during their most recent anal sex encounter with a
nonprimary partner. The three groups significantly (p,0.05) reduced risk behavior (e.g., unprotected anal sex reduced by
32% at 12-mo follow-up), but were not different (p.0.05) from each other at 3-, 6-, and 12-mo follow-up. Outcomes for the
2-arm comparisons were not significantly different at 12-mo follow-up (e.g., unprotected anal sex, odds ratio=1.14,
confidence interval=0.86–1.51), nor at earlier time points. Similar results were found for each outcome variable in both 2-
and 3-arm comparisons.
Conclusions: These results for reducing sexual risk behavior of substance-using MSM are consistent with results of
intervention trials for other populations, which collectively suggest critical challenges for the field of HIV behavioral
interventions. Several mechanisms may contribute to statistically indistinguishable reductions in risk outcomes by trial
group. More explicit debate is needed in the behavioral intervention field about appropriate scientific designs and methods.
As HIV prevention increasingly competes for behavior-change attention alongside other ‘‘chronic’’ diseases and mental
health issues, new approaches may better resonate with at-risk groups.
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Men who have sex with men (MSM) continue to be the largest
group newly HIV infected each year in the United States [1].
Alcohol and noninjection substance use is associated with sexual
risk behavior in this population [2–8], and sexual risk increases
when substances are used soon before or during sexual encounters
[4,9]. Thus, substance-using MSM are likely to be contributing
disproportionately to HIV incidence in the US [10]. Although
interventions have been tested with substance-abusing MSM in
drug treatment settings [11–13], few interventions have been
tested with substance-using MSM not in treatment [14]. This
study is, to our knowledge, the first large, multicity, randomized
intervention trial specifically addressing sexual risk among out-of-
treatment substance-using MSM.
Randomized trials of HIV risk behavioral interventions [15–
18]—particularly for MSM—have generally used two-group
designs: an attention-control group (e.g., content materials
unrelated to intervention content) or a standard group (e.g.,
HIV counseling and testing), but rarely both. These interventions
generally found no difference between the two groups in HIV risk
outcomes [15–18]. An ideal approach is a three-group trial that
distinguishes the effects of content and attention. We used a
modified three-group design: randomized intervention and
attention-control groups and a nonrandomized standard group.
The research objective was to systematically test the efficacy of a
group-based, cognitive-behavioral intervention to reduce sexual
risk of substance-using MSM.
Methods
The protocol (Text S1) was approved by institutional review
boards at each of the local sites and the Centers for Disease
Control and Prevention (CDC). Details of the baseline assessment
have been published [2]. The CONSORT requirements (Text S2)
were completed as requested.
Study Population
Participants for all three groups were recruited and assessed
through follow-up in Chicago, Los Angeles, New York City, and
San Francisco, from October 2004 through April 2008, through
street and MSM venue outreach, agency/business-based posters
and flyers, ads in print media, and word of mouth. Each city
tailored its recruitment campaigns to the local population.
Standard power analysis calculations were conducted a priori to
determine the desired sample size, based on 80% statistical power
to detect a 25% reduction in risk behavior, and an expected 80%
retention across follow-up waves.
Men were eligible to participate if they reported (1) being
drunk or ‘‘buzzed’’ on alcohol two or more times, or high on
noninjection drugs at least once, during (or 2 h before) anal sex
in the past 6 mo, and (2) at least one unprotected anal sex
episode in the past 6 mo with a male partner whose HIV
serostatus was unknown or different from their own. Men were
ineligible if they (1) reported only marijuana or use of erectile
dysfunction medications soon before or during anal sex in the
past 6 mo; (2) reported injecting drugs other than steroids,
hormones, prescribed medications, or methamphetamine in the
past 6 mo; (3) had known for less than 6 mo that they were
HIV-positive; or (4) were currently participating in another HIV
behavioral intervention trial. For the two randomized groups,
eligible men agreed to participate in a six-session, group-based
intervention and to complete assessments at baseline and at 3-,
6-, and 12-mo follow-up waves. For the standard group, eligible
men agreed to complete an asses s m e n ta tb a s e l i n ea n da t3 - m o
follow-up.
Design and Procedures
Screening. Potential participants were initially screened by
telephone. Those who were eligible and willing to participate were
scheduled for a baseline appointment; HIV-positive men were
asked to bring documentation of their serostatus (e.g., HIV-
positive test result or treatment prescription) to the appointment.
Baseline assessment. At the baseline assessment, men were
rescreened for eligibility. If eligible, the men provided written
informed consent and completed an audio computer-assisted self-
interview (ACASI). All men received standard HIV risk-reduction
counseling [19]; HIV-negative and unknown-serostatus men and
HIV-positive men without documentation of their serostatus were
administered a rapid HIV test. Contact information was collected,
and the next appointment was scheduled (i.e., group ran-
domization for the intervention and attention-control groups;
and 3-mo follow-up for the standard group). Lastly, the men were
reimbursed for their time and travel, as determined by each site
(range, US$25–US$40). The assessment collected information
on demographic characteristics, substance use, and sexual risk
behavior during the participant’s most recent anal sex encounter,
and psychosocial and mental health measures. We took steps to
minimize bias, including the use of different staff members for
group activities versus assessment. Perhaps more important,
behavior was assessed in a private location by the use of ACASI.
Randomization. Participants were randomized by laptop
computer program to intervention and attention-control groups
upon arrival at the first group session. A minimum of ten (five per
group) and a maximum of 20 (ten per group) men were needed for
randomization. On-site computerized randomization was blocked
by HIV serostatus so that if possible, the intervention and the
attention-control group each contained at least two men who were
HIV-positive and at least two men who were HIV-negative
(participant code and blocking information were pre-entered into
the computer prior to the first session). Each group was also
blocked for a minimum of five participants. Randomization
stopped after 20; men who arrived later were reimbursed US$15
for transportation costs and if possible, rescheduled for another
randomization session.
Because of insufficient funding to fully randomize all three
groups, enrollment in the standard group took place immediately
after enrollment in the intervention and attention-control groups
had been completed. Even though enrollment for the two
randomized immediately preceded enrollment for the nonrando-
mized control group, follow-up assessment overlapped for the
three groups.
Group sessions. Intervention and attention-control groups
consisted of six weekly 2-h group sessions, facilitated by trained
staff (facilitator protocols available from G. Mansergh, on request).
Intervention content consisted of cognitive-behavioral techniques
and relevant skills building [20,21], including modeling and
behavioral rehearsal. Specific intervention modules helped
participants analyze their substance use and sexual risk patterns,
identify situational triggers for risky behavior, develop behavioral
alternatives and negotiation strategies, and plan for change.
Behavior change attempts over the 6 wk allowed for feedback and
positive reinforcement on a weekly basis. Intervention content was
based on formative research and pilot testing. A 10-min break
occurred in the middle of each weekly 2-h session.
The modules of the attention-control group consisted of videos,
and group discussion was focused on MSM-related issues
unrelated to substance use, sexual risk behavior, and HIV, such
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modules each consisted of a 20- to 30-min video followed by
discussion of the video; two modules were presented each meeting
of the 6 wk, with a 10-min break in the middle of each night.
Staff members were extensively trained to facilitate the
intervention and attention-control materials according to the
facilitator manuals. For the intervention group, staff were trained
to lead intervention exercises and discussions, emphasizing
primary messages. For the attention-control group, staff were
trained to subtly redirect discussion—away from substance use,
sexual risk behavior, and HIV/AIDS. Intervention and attention-
control group sessions were taped, and two of the six sessions for
each group were reviewed and scored to ensure that the material
in the facilitator manuals was covered. For the intervention group,
adherence to the materials during the six sessions averaged 94%.
For the attention-control group, intervention content (alcohol or
drug use, sexual risk, and HIV/AIDS) discussion was to be
avoided; unintended discussion of topics related to HIV, substance
use, or sexual risk behaviors occurred in 3% of the sessions and
were redirected by facilitators.
Follow-up assessment. For the intervention and attention-
control groups, follow-up assessment waves took place 3, 6, and
12 mo after the final group session. In follow-up sessions,
participants completed the same ACASI behavioral assessment
as at baseline, updated their contact information, were reimbursed
for time and travel (increasing at each follow-up, ranging from
US$25–US$50), and received an appointment for the next follow-
up. The 12-mo follow-up included HIV testing for HIV-negative
participants and counseling for all participants. For the standard
group, follow-up assessment took place at 3 mo plus 7 wk (to
control for lag time because of completion of sessions in the other
two groups).
Statistical Analysis
The level of significance for all tests was set at p,0.05. Sample
size was based on 80% statistical power to detect an approximate
25% change in behavior (e.g., unprotected anal sex) from baseline
to follow-up, which is consistent with findings from meta-analyses
of HIV behavioral intervention trials [22,23]. Bivariate compar-
isons of outcomes and predictors at each follow-up wave were
performed with chi-square tests; 95% confidence intervals (CIs) for
raw proportions were calculated with asymptotic standard errors
and a continuity correction.
The primary outcomes were six dichotomous variables, all
focused on participant behavior during the most recent anal sex
encounter with a nonprimary partner: (1) unprotected anal sex; (2)
unprotected anal sex with a discordant partner (i.e., a partner
whose HIV serostatus was unknown or different from that of the
participant); (3) alcohol use soon before or during unprotected anal
sex; (4) alcohol use during or before unprotected anal sex with a
discordant partner; (5) drug use soon before or during unprotected
anal sex; and (6) drug use soon before or during unprotected anal
sex with a discordant partner. Three secondary outcomes of
interest were (1) unprotected receptive anal sex, (2) unprotected
insertive anal sex, and (3) substance (alcohol or drug) use soon
before or during anal sex, whether protected or unprotected anal
sex.
For longitudinal analyses, we used a generalized linear mixed
model to evaluate the dichotomous outcomes. A random intercept
for each participant was incorporated into the model to control for
any correlation within participants in the four follow-up waves.
The set of covariates consisted of site (Chicago, Los Angeles, New
York, San Francisco), age (18–24, 25–34, 35–44, $45 y),
education level (high school diploma or less, some post-high
school training, college degree or more), primary race or ethnicity
(black, Hispanic/Latino, white, other), self-identified as gay/
homosexual (bisexual/other), self-reported baseline HIV serosta-
tus, assessment wave (baseline: 3-, 6-, and 12-mo follow-up), and
trial group (intervention, attention-control, standard group;
blinded in analysis), as well as an interaction between follow-up
wave and trial group to test for efficacy.
A generalization of the Satterthwaite approximation [24] was
used to adjust the degrees of freedom. We used a multiple
imputation approach [25] with adaptive rounding for binary
variables [26] to impute missing outcome variables. Ten
imputations were aggregated for the results and drug use
covariates were incorporated into the imputation procedure to
increase the efficiency of the imputed observations [27]. Models
were also run on the raw, nonimputed data. Inferences for the trial
arm, wave, and interaction between trial arm and wave did not
differ between the analyses of the raw and multiply imputed data.
Rates of reduction were calculated from population-averaged
rates, which control for all other covariates in the multivariable
model. Models were calculated by using the GLIMMIX and
MIANALYZE procedures in Statistical Analysis Software (SAS),
version 9.2 (SAS Institute, Inc.), and model fit was evaluated by
diagnostic statistics and residual plots.
Results
Sample Characteristics
In total, 1,686 men were enrolled: 1,206 were randomly
assigned to the intervention and attention-control groups; 480
were assigned to the standard group (Table 1). The sample was
diverse in terms of age, race/ethnicity, baseline self-reported HIV
serostatus, and education level. Nearly one in six men did not
identify themselves as gay or homosexual. There were no
differences (p.0.05) in descriptive characteristics for the two
randomized groups. Participants in the standard group were
younger and more educated, and fewer were black or HIV-
positive (p,0.05).
Enrollment and Retention
For randomization of the intervention and attention-control
groups, 7,370 men were screened, and 1,206 were enrolled at the
randomization session (n=599 in intervention group; n=607 in
attention-control group; Figure 1). A total of 2,656 men were
screened for the standard group to achieve enrollment of 480.
Session attendance and retention were high throughout the trial
(Figure 1). Session attendance for the two randomized groups did
not differ (p.0.05): attendance at each session after session 1
ranged from 73% to 79%. Retention at follow-up for these groups
also did not differ (p.0.05): retention at each follow-up wave
ranged from 87% to 90%. For the standard group, retention at 3-
mo follow-up was lower: 78%.
Attrition analysis of follow-up waves for the two randomized
groups found no differences (p.0.05) in main effects of follow-up
wave and group, or in interaction effects of follow-up wave by
group. Further, unprotected anal sex and discordant unprotected
anal sex were not associated (p.0.05) with loss to follow-up.
Attrition analysis at 3-mo follow-up for the three groups found
greater (p,0.05) loss to follow-up in the nonrandomized group
than in the randomized groups. Again, unprotected anal sex and
discordant unprotected anal sex were not associated with attrition.
In comparisons by age and education, more of the youngest
participants (18–24 y versus $45 y) and those with the least
education (high school diploma or less versus college degree or
higher) were missing at 3-mo follow-up (p,0.05).
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Characteristic Intervention (n=599) Attention Control (n=607) Standard (n=480)
n (%) n (%) n (%)
Age group (y) 18–24 70 (12) 56 (9) 64 (13)
a
25–34 158 (26) 162 (27) 150 (31)
35–44 239 (40) 265 (44) 168 (35)
#45 132 (22) 124 (20) 98 (21)
Primary race/ethnicity Black 200 (33) 194 (32) 124 (26)
a
Hispanic/Latino 120 (20) 102 (17) 97 (20)
White 225 (38) 241 (40) 216 (45)
Other 54 (9) 70 (11) 43 (9)
Education level #High school diploma 190 (32) 191 (31) 111 (23)
a
.High school education 198 (33) 216 (36) 179 (37)
$College degree 211 (35) 200 (33) 190 (40)
HIV serostatus Positive 307 (51) 300 (49) 178 (37)
a
Negative 248 (42) 272 (45) 245 (51)
Unknown 44 (7) 35 (6) 57 (12)
Sexual orientation identification Gay/homosexual 501 (84) 508 (84) 410 (85)
Bisexual/other 98 (16) 99 (16) 70 (15)
City Chicago 159 (27) 160 (26) 150 (31)
Los Angeles 118 (20) 118 (20) 99 (21)
New York 151 (25) 159 (26) 102 (21)
San Francisco 171 (28) 170 (28) 129 (27)
aStandard group significantly different from intervention and attention-control groups (chi-square test, p,0.05); other overall 3-way tests were nonsignificant (p.0.05).
doi:10.1371/journal.pmed.1000329.t001
Figure 1. CONSORT flow diagrams. (A) October 2004–April 2008 (screen through 3, 6, and 12-mo follow-up): randomized intervention and
attention-control groups. (B) December 2006–September 2007 (screen through 3-mo follow-up): nonrandomized standard control group.
doi:10.1371/journal.pmed.1000329.g001
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At baseline, two-thirds of the sample reported that they had not
used protection during their most recent anal sex encounter
(Table 2). Two of every five men reported discordant unprotected
anal sex. More than three-fourths of the sample reported at baseline
that they had used alcohol or drugs soonbefore or during their most
recent anal sex encounter: 57% reported alcohol use, and 56%
reported drug use (unpublished data). Over 40% of the sample
reported alcohol use,andover 40%reported drug use beforehaving
unprotected sex in their most recent anal sex encounter; 25%
reported alcohol and 25% reported drug use before having
discordant unprotected sex in that encounter. The three groups
did not differ at baseline on any of these risk behaviors (Table 2).
Study Outcomes
Risky behavior was lower at 3-, 6-, and 12-mo follow-up waves
for the primary and secondary outcome variables in all trial groups
(Table 2). In multivariate analysis, controlled for demographic
variables (Table 3), each of the primary outcomes significantly
(p,0.05) decreased at 3-mo follow-up. These reductions were
maintained at 6- and 12-mo follow-up for the intervention and
attention-control groups. For example, in the 2-arm comparison,
the population-averaged means indicated unprotected anal
intercourse in the prior 3 mo reduced by 32% at 12-mo (27% at
3-mo and 29% at 6-mo) follow-up relative to the baseline rate; the
reductions did not differ by follow-up wave (p.0.05). After
standardizing the reductions, similar results were found for the
other outcome variables at each of the follow-up time points in 2-
arm comparisons, and at 3-mo follow-up for 3-arm comparisons
(Table 3). The pattern was similar for the secondary outcome
variables: unprotected receptive sex, unprotected insertive sex, and
substance use before anal sex. Multivariate analysis found no
differences (Table 3) between the randomized intervention and
attention-control group for outcome variables at each of the
follow-up waves. For example, the outcomes for the 2-arm
comparison were not significantly different at 12-mo follow-up
(e.g., unprotected anal [UA] sex, odds ratio [OR]=1.14, 95%
CI=0.86–1.51; HIV-discordant UA [DUA], OR=0.92,
CI=0.66–1.28; alcohol UA, OR=1.06, CI=0.75–1.49; drug
UA, OR=1.21, CI=0.86–1.70; alcohol DUA, OR=0.86,
CI=0.56–1.32; drug DUA, OR=0.98, CI=0.64–1.48). Further,
there were no differences in any of the outcomes between all three
groups at 3-mo follow-up (Table 3). The pattern of results was
notably consistent for the 18 analysis models presented in Table 3,
and thus likely not due to chance.
Discussion
In this cognitive-behavioral intervention trial, the three groups
significantly reduced risk behavior to similar levels at each follow-up
time point (e.g., overall 32% reduction in UA at 12-mo follow-up)
and were not different from one another. These trial results for
reducing risk behavior of substance-using MSM are consistent with
results of other randomized intervention trials for MSM and
substance-using populations [15–18], which collectively point to
critical challenges for the field of HIV behavioral interventions and
perhaps interventions for other health behaviors as well. For
example, a systematic review of multibehavior interventions to
reduce risk for coronary heart disease [28] found that the
interventions had little or no impact on risk of heart disease, and
only small reductions in more proximal indicators (e.g., salt intake,
cholesterol, and blood pressure levels). The authors concluded that
althoughnumerousstudieshavebeen done,attemptsatreductionin
behavior-related risk factors for heart disease have limited success.
Perhaps more intensive, multilevel interventions (i.e., interventions
that address more than one level, including individual, small group,
community, and structural levels) are needed to provide preferential
results compared to control groups [29]; interventions that focus on
more structural and policy level interventions (e.g., free and
accessible condoms) could provide broader and more impactful
behavior change [29]. Such an approach to behavioral interven-
tions for substance-using MSM may be warranted.
Table 2. Project MIX primary and secondary outcome behaviors, by group at assessment wave, 2004–2008.
Behavior Soon Before
or During Most Recent
Anal Sex Encounter Baseline (%) 3 mo (%) 6 mo (%) 12 mo (%)
Interv
(n=599)
Attn
(n=607)
Stand
(n=480)
Interv
(n=524)
Attn
(n=537)
Stand
(n=374)
Interv
(n=520)
Attn
(n=538)
Interv
(n=537)
Attn
(n=542)
Primary outcome
UA 67 68 68 43 44 43 43 42 40 38
DUA 39 38 43 19 21 23 17 18 18 20
Substance use and UA
Alcohol 42 40 42 21 21 21 20 21 17 17
Drugs 45 43 39 26 24 22 27 23 22 19
Substance use and DUA
Alcohol 27 23 28 10 11 13 8 9 9 10
Drugs 25 24 24 12 12 11 10 9 10 11
Secondary outcome
URA 38 41 39 24 26 25 23 24 25 22
U I A 3 93 63 52 42 22 12 42 32 02 0
Substance use 77 78 75 54 52 53 52 49 46 44
Attn, attention-control group; Interv, intervention group; Stand, standard group; URA, unprotected receptive anal sex; UIA, unprotected insertive anal sex.
doi:10.1371/journal.pmed.1000329.t002
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comparison groups in this trial may be similar for several reasons.
First, regression to the mean may account for behavioral risk
reduction at follow-up for all groups [30]. Second, perhaps
standard HIV counseling and testing are adequate to reduce risk,
and more intensive interventions provide no additional benefit. In
fact, some studies have found HIV testing to reduce measures
of risk [19], as have studies of brief counseling [20,21]. Brief
Table 3. Project MIX, multivariate results for outcome behaviors, by group at assessment wave, 2004–2008.
Group Primary Outcomes, AOR (CI) Secondary Outcomes, AOR (CI)
UA DUA
Alcohol-
UA
Drug-
UA
Alcohol-
DUA
Drug-
DUA URA UIA
Substance
Use during
Sex
a
2-Group analysis for
3-, 6-, 12-mo follow-up
waves (n=1,206)
Attention-control (referent)
Intervention 0.95
(0.72–1.26)
1.06
(0.82–1.38)
1.15
(0.88–1.50)
1.07
(0.81–1.42)
1.25
(0.93–1.67)
1.04
(0.77–1.40)
0.85
(0.64–1.13)
1.15
(0.87–1.52)
0.96
(0.70–1.30)
Follow-up (baseline, referent)
3 mo 0.34
(0.26–0.43)
0.41
(0.31–0.54)
0.37
(0.28–0.49)
0.36
(0.27–0.47)
0.40
(0.29–0.57)
0.42
(0.30–0.58)
0.46
(0.35–0.61)
0.48
(0.36–0.63)
0.27
(0.21–0.36)
6 mo 0.29
(0.23–0.38)
0.34
(0.25–0.45)
0.37
(0.28–0.49)
0.32
(0.24–0.42)
0.32
(0.23–0.45)
0.28 (0.19–
0.40)
0.40
(0.30–0.53)
0.50
(0.37–0.66)
0.24
(0.18–0.31)
12 mo 0.24
(0.18–0.31)
0.37
(0.28–0.49)
0.27
(0.20–0.36)
0.25
(0.18–0.33)
0.34
(0.24–0.48)
0.33
(0.24–0.47)
0.33
(0.25–0.43)
0.40
(0.31–0.54)
0.19
(0.14–0.25)
Intervention group comparisons
Baseline—Interv (versus Attn) 0.95
(0.71–1.27)
1.06
(0.81–1.39)
1.15
(0.88–1.51)
1.07
(0.80–1.43)
1.25
(0.92–1.69)
1.04
(0.76–1.41)
0.85
(0.63–1.14)
1.15
(0.86–1.53)
0.96
(0.69–1.32)
3 mo—Interv (versus Attn) 0.93
(0.70–1.22)
0.89
(0.64–1.23)
0.99
(0.72–1.37)
1.06
(0.77–1.46)
0.88
(0.58–1.32)
0.92
(0.62–1.37)
0.86
(0.63–1.19)
1.11
(0.81–1.53)
1.13
(0.85–1.49)
6 mo—Interv (versus Attn) 1.01
(0.76–1.33)
0.89
(0.64–1.25)
0.94
(0.68–1.30)
1.26
(0.91–1.75)
0.87
(0.56–1.35)
1.14
(0.74–1.76)
0.94
(0.67–1.30)
1.03
(0.75–1.42)
1.12
(0.85–1.49)
12-mo—Interv (versus Attn) 1.14
(0.86–1.51)
0.92
(0.66–1.28)
1.06
(0.75–1.49)
1.21
(0.86–1.70)
0.86
(0.56–1.32)
0.98
(0.64–1.48)
1.27
(0.91–1.77)
1.05
(0.75–1.47)
1.10
(0.83–1.45)
3-Group analysis for 3-mo
follow-up waves (n=1,686)
Standard (referent)
Intervention 0.93
(0.71–1.23)
0.87
(0.67–1.13)
1.00
(0.77–1.31)
1.13
(0.86–1.48)
0.97
(0.73–1.30)
1.00
(0.74–1.36)
0.84
(0.64–1.12)
1.17
(0.89–1.54)
1.04
(0.77–1.40)
Attention-control 0.97
(0.74–1.28)
0.84
(0.64–1.09)
0.88
(0.68–1.15)
1.05
(0.80–1.38)
0.80
(0.59–1.07)
0.97
(0.71–1.31)
0.98
(0.74–1.30)
1.03
(0.78–1.35)
1.09
(0.81–1.48)
Follow-up (baseline, referent)
3-mo 0.34
(0.26–0.45)
0.39
(0.29–0.53)
0.35
(0.26–0.47)
0.39
(0.29–0.53)
0.35
(0.25–0.5)
0.39
(0.27–0.57)
0.52
(0.37–0.72)
0.50
(0.36–0.69)
0.37
(0.27–0.49)
Intervention group comparisons
Baseline—Interv (versus Attn) 0.96
(0.73–1.26)
1.05
(0.81–1.35)
1.14
(0.88–1.47)
1.07
(0.82–1.39)
1.22
(0.91–1.62)
1.04
(0.77–1.39)
0.86
(0.65–1.13)
1.14
(0.88–1.49)
0.95
(0.70–1.28)
Baseline—Interv (versus Stand) 0.93
(0.70–1.24)
0.87
(0.67–1.14)
1.00
(0.77–1.32)
1.13
(0.85–1.50)
0.97
(0.72–1.31)
1.00
(0.73–1.37)
0.84
(0.63–1.13)
1.17
(0.88–1.56)
1.04
(0.76–1.42)
Baseline—Attn (versus Stand) 0.97
(0.73–1.30)
0.84
(0.64–1.09)
0.88
(0.67–1.16)
1.05
(0.79–1.39)
0.80
(0.59–1.08)
0.97
(0.70–1.32)
0.98
(0.74–1.32)
1.03
(0.77–1.37)
1.09
(0.80–1.50)
3 mo—Interv (versus Attn) 0.95
(0.73–1.23)
0.88
(0.65–1.20)
1.00
(0.74–1.36)
1.06
(0.79–1.42)
0.86
(0.58–1.27)
0.93
(0.64–1.36)
0.88
(0.65–1.19)
1.15
(0.85–1.54)
1.12
(0.87–1.45)
3 mo—Interv (versus Stand) 0.95
(0.72–1.25)
0.78
(0.57–1.08)
0.98
(0.71–1.36)
1.09
(0.79–1.51)
0.79
(0.53–1.19)
0.96
(0.63–1.45)
0.80
(0.58–1.11)
1.18
(0.86–1.63)
0.98
(0.74–1.29)
3 mo—Attn (versus Stand) 0.99
(0.75–1.31)
0.89
(0.65–1.22)
0.98
(0.71–1.36)
1.03
(0.74–1.43)
0.93
(0.62–1.38)
1.03
(0.69–1.55)
0.91
(0.66–1.26)
1.03
(0.75–1.42)
0.87
(0.67–1.15)
Controlled for all variables listed plus city, age, race/ethnicity, education level, sexual orientation identification, and HIV serostatus.
AOR, adjusted odds ratio; Attn, attention-control group; Interv, intervention group; Stand, standard of care group; UIA, unprotected insertive anal sex; URA, unprotected
receptive anal sex.
aSubstance use soon before or during most recent anal sex encounter.
doi:10.1371/journal.pmed.1000329.t003
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change, as in persons willing to enroll in an intervention trial such
as ours.
Another possible mechanism for reported risk reduction across
groups is that a trial’s unintentional ‘‘demand’’ for change
(through the psychosocial dynamics of selective recall and social
desirability) reduces reports of risky behavior but does not reduce
the risky behavior itself. We did not find a relationship between a
standard measure of social desirability and risk reports in this
cohort, although general social desirability measures may not
accurately assess the dynamic in the context of this study. A well-
designed methodological study would have to examine potential
mediators of real and reported behavior change; for example,
including a post-test–only intervention condition and an assess-
ment-only condition (e.g., the Solomon Four-Group Design) could
test this approach. During repeated assessments, some men may
learn (and choose) to complete their follow-up assessment more
quickly by reporting less risk, although we did not find this to be a
clear pattern in our trial.
Our trial had several limitations, including standard concerns in
behavioral research regarding self-report (although we did use
ACASI to minimize this bias) [31], and behavioral regression to
the mean over time, as mentioned [30]; this may especially be the
case with the very high-risk enrollment criteria in this study (i.e.,
greater potential for regression to the mean at follow-up relative to
less-risky samples). Not all of the outcome variables are entirely
exclusive from one another (e.g., UA with a discordant partner is
subsumed in UA overall). Although the intervention and attention-
control groups were randomized, the standard group was not:
because of funding restrictions, enrollment for the standard group
took place after enrollment for the other groups, and this group
provided only a 3-mo follow-up. Although a few demographic
differences were noted between the standard group and the other
groups at baseline, baseline risk behavior did not differ; we
controlled for baseline demographic factors in outcome analyses,
and there were no group differences.
Future methodological studies should systematically assess
effects of behavioral intervention methods, including potential
change mechanisms noted above, which could inform other areas
of health behavior research as well as HIV prevention, particularly
in the context of multilevel interventions. If recommended
counseling and testing [19] constitute an acceptable standard for
reducing risk behavior, then perhaps this type of counseling and
testing is an appropriate comparison group in trials, especially
given that expensive attention-control groups prohibit inclusion of
other methodologically important groups (e.g., assessment only;
post-test only). More explicit debate is needed in the HIV
behavioral intervention field about appropriate study methods and
designs, and new paradigms should be explored.
Alcohol- and drug-using MSM contribute to HIV incidence
among US MSM, and they are a critical group for focused risk
reduction [32]; this is one of the first and the largest intervention
trials tested on this high-risk population to our knowledge. To
achieve behavior change beyond that of standard HIV counseling
and testing, new approaches should be considered. Colleagues
have suggested a focus on ‘‘syndemics’’ of HIV, substance use,
depression, etc. [33], and broader perspectives on health and
healthy lifestyles beyond HIV. Similarly, ‘‘positive psychology’’
and a focus on health strengths is an emerging direction for the
field of health research [34]. Holistic approaches such as these may
increasingly resonate, as HIV prevention competes more and
more for behavior-change attention alongside traditional chronic
diseases and mental health issues [35]. Other possible directions
for future research include a focus on environmental factors that
affect sexual risk behavior of substance-using MSM, and
enhancing behavioral uptake and adherence of promising
biomedical interventions for high-risk MSM [35], such as pre-
and post-exposure prophylaxis.
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Background. AIDS first emerged in the early 1980s among
gay men living in the US. As the disease spread around the
world, it became clear that AIDS also affects heterosexual
men and women. Now, three decades on, more than 30
million people are infected with HIV, the virus that causes
AIDS. HIV is most often spread by having unprotected sex
with an infected partner and, globally, most sexual
transmission of HIV now occurs during heterosexual sex.
However, 5%–10% of all new HIV infections still occur in men
who have sex with men (MSM, a term that encompasses gay,
bisexual, transgendered, and heterosexual men who
sometimes have sex with men) and, in several high-income
countries, male-to-male sexual contact remains the most
important HIV transmission route. In the US, for example,
more than half of the approximately 50,000 people who
become infected with HIV every year do so through male-to-
male sexual contact.
Why Was This Study Done? In countries where MSM are
the group at highest risk of HIV infection, any intervention
that reduces HIV transmission in MSM should have a major
effect on the overall HIV infection rate. Among MSM, sexual
behaviors that increase the risk of HIV infection (for example,
not using a condom, having anal sex, having sex with a
partner of unknown HIV status, and having sex with many
partners) are associated with the use of alcohol and
noninjection drugs (for example, inhaled amyl nitrite or
poppers) during or shortly before sexual encounters. In this
study (Project MIX), the researchers investigate whether a
group-based behavioral intervention reduces sexual risk
behavior in substance-using MSM.
What Did the Researchers Do and Find? The researchers
recruited substance-using MSM from four US cities who had
had risky sex at least once in the past 6 months. Participants
were randomized to a cognitive-behavioral intervention or to
an attention-control group; a third, nonrandomized group of
MSM formed a standard HIV counseling and testing only
group. All the groups had HIV counseling and testing at the
start of the study and completed a questionnaire about their
substance use and sexual risk behavior during their most
recent anal sex encounter. The cognitive-behavior group
then received six weekly 2-hour group sessions focused on
reducing substance use and sexual risk behavior by helping
the men change their thinking (cognition) and behavior
regarding sexual risk taking. The attention-control group
received six group sessions about general MSM issues such
as relationships, excluding discussion of substance use, and
sexual risk behavior. The participants in both of these groups
completed the questionnaire about their substance use and
sexual risk behavior again at 3, 6, and 12 months after the
group sessions; the participants in the standard HIV
counseling and testing group completed the questionnaire
again about 5 months after completing the first
questionnaire (to control for the time taken by the other
two groups to complete the intervention). At baseline, about
67% of the participants reported unprotected anal sex and
77% reported substance use during their most recent anal
sex encounter with a nonprimary partner. At the 3-month
follow-up, the incidence of sexual risk behavior had fallen to
about 43% in all three groups; the incidence of substance
use during sex had fallen to about 50%. Risk taking and
substance use remained at these levels in the intervention
and attention-control groups at the later follow-up time
points.
What Do These Findings Mean? These findings suggest
that this cognitive-behavioral intervention is no better at
reducing sexual risk taking among substance-using MSM
than is an unrelated video-discussion group or standard HIV
counseling and testing. One explanation for this negative
result might be that brief counseling is especially effective
with people who are ready for a change such as MSM willing
to enroll in an intervention trial of this type. Alternatively,
just being in the trial might have encouraged all the
participants to self-report reduced risk behavior. Thus,
alternative scientific designs and methods might be
needed to find behavioral interventions that can effectively
reduce HIV transmission among substance-using MSM and
other people at high risk of HIV infection. Importantly,
however, these findings raise the question of whether more
extensive, multilevel interventions or broader lifestyle and
positive health approaches (rather than single-level or single-
subject behavioral interventions) might be needed to reduce
sexual risk behavior among substance-using MSM.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000329.
N Information is available from the US Department of Health
and Human Services on HIV prevention programs,
research, and policy
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS, including information on HIV transmission and
transmission in gay men and other MSM, on substance
abuse and HIV/AIDS, and on safer sex
N Information is available from Avert, an international AIDS
nonprofit, on all aspects of HIV/AIDS, including information
on HIV, AIDS, and men who have sex with men and on
drink, drugs, and sex (in English and Spanish)
N The US Centers for Disease Control and Prevention also
have information for the public and for professionals about
HIV/AIDS among men who have sex with men (in English
and Spanish)
N The US National Institute on Drug Abuse has information
on HIV/AIDS and drug abuse, including a resource aimed at
educating teenagers about the link between drug abuse
and the spread of HIV in the US (in English and Spanish)
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